Literature DB >> 14983502

The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors.

Smadar Avigad1, Ian J Cohen, Julia Zilberstein, Ella Liberzon, Yacov Goshen, Shifra Ash, Isaac Meller, Yehuda Kollender, Josephine Issakov, Rina Zaizov, Isaac Yaniv.   

Abstract

BACKGROUND: Tumors in the Ewing family (EFTs) are the second most common bone tumors in children and adolescents. Despite aggressive chemotherapy, one-third of patients with localized tumor still may develop recurrences. This implies that not all tumor cells are eradicated and that the patients may have a level of residual disease. EFTs are characterized by specific chromosomal translocations that result in chimeric transcripts that can be detected with reverse transcriptase-polymerase chain reaction (RT-PCR) analysis.
METHODS: The authors report the prognostic potential of the positive chimeric transcript (EWS/FLI1) in bone marrow (BM) and/or peripheral blood (PBL) in 26 patients with EFT during a long follow-up period (median, 61 months).
RESULTS: At diagnosis, 43% of patients had positive RT-PCR BM results, with no correlation to tumor progression (P = 0.3). During follow-up, 58% of patients had positive RT-PCR results in their last sample analyzed (BM and/or PBL). A highly significant correlation between the presence of the chimeric transcript and disease progression was detected (P = 0.0028). In a multivariate analysis, the percentage of tumor necrosis (P = 0.007) and RT-PCR results during follow-up (P = 0.02) remained significant prognostic markers. In 10 of 11 patients who developed disease progression, BM and/or PBL samples were positive for the chimeric transcript before evidence of overt clinical recurrence.
CONCLUSIONS: Occult tumor cells in BM and/or PBL samples during long follow-up are strong predictors of recurrent disease in patients with nonmetastatic EFTs. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14983502     DOI: 10.1002/cncr.20059

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay.

Authors:  Soledad Gallego; Anna Llort; Josep Roma; Constantino Sabado; Luis Gros; Josep Sanchez de Toledo
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-25       Impact factor: 4.553

2.  Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas.

Authors:  Neerav N Shukla; Juber A Patel; Heather Magnan; Ahmet Zehir; Daoqi You; Jiabin Tang; Fanli Meng; Aliaksandra Samoila; Emily K Slotkin; Srikanth R Ambati; Alexander J Chou; Leonard H Wexler; Paul A Meyers; Ellinor I Peerschke; Agnes Viale; Michael F Berger; Marc Ladanyi
Journal:  JCO Precis Oncol       Date:  2017-05-23

3.  Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma.

Authors:  David Boyce-Fappiano; B Ashleigh Guadagnolo; Ravin Ratan; Wei-Lien Wang; Michael J Wagner; Shreyaskumar Patel; John A Livingston; Patrick P Lin; Kevin Diao; Devarati Mitra; Ahsan Farooqi; Alexander J Lazar; Christina L Roland; Andrew J Bishop
Journal:  Oncologist       Date:  2020-12-14

Review 4.  Circulating tumor cells in sarcomas: a brief review.

Authors:  Le Chang; Greg Asatrian; Sarah M Dry; Aaron W James
Journal:  Med Oncol       Date:  2014-12-10       Impact factor: 3.064

Review 5.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.

Authors:  Iranzu González; Silvestre Vicent; Enrique de Alava; Fernando Lecanda
Journal:  J Mol Med (Berl)       Date:  2007-04-24       Impact factor: 4.599

Review 7.  Ewing's sarcoma: standard and experimental treatment options.

Authors:  Vivek Subbiah; Pete Anderson; Alexander J Lazar; Emily Burdett; Kevin Raymond; Joseph A Ludwig
Journal:  Curr Treat Options Oncol       Date:  2009-06-17

Review 8.  Extraosseous Ewing Sarcoma: Diagnosis, Prognosis and Optimal Management.

Authors:  George Galyfos; Georgios A Karantzikos; Nikolaos Kavouras; Argiri Sianou; Konstantinos Palogos; Konstantinos Filis
Journal:  Indian J Surg       Date:  2015-11-13       Impact factor: 0.656

9.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

Review 10.  Molecular pathology of sarcomas: concepts and clinical implications.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-09-29       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.